RxDoctor Payments DataLook up a doctor →

Jessica Ailani, MD

Neurology · Washington, DCNPI 1073703096

Payments from drug & device makers

$1,485,970in general payments, 2019–2025

Across 1,406 payments — averaging $1056.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$536K
  • Pfizer$250K
  • Lilly USA, LLC$185K
  • Lundbeck LLC$115K
  • H. Lundbeck A S$93K
  • Teva Pharmaceuticals USA, Inc.$64K
  • plus $242K from 34 others
$51,277in research payments, 2019–2025

Across 28 payments — averaging $1831.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$18K
  • Eli Lilly$17K
  • Pfizer$13K
  • Novartis$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,485,970 in reported general payments places this provider in the 90th percentile of 113 neurology providers in District of Columbia.

See all neurology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$330,467
Medicare patients
159
Services billed
37,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →